Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma

被引:22
作者
Zhao, Hai-Tao [1 ]
Chen, Jing [2 ]
Shi, Sheng-bin [3 ]
Tian, Jing [3 ]
Tao, Rong-Jie [1 ]
机构
[1] Shan Dong Tumor Hosp, Dept Neurosurg, Jinan 250117, Shandong, Peoples R China
[2] Shandong Univ, Jinan Cent Hosp, Dept Neurol, Jinan 250013, Shandong, Peoples R China
[3] Shan Dong Tumor Hosp, Dept Oncol, Jinan 250117, Shandong, Peoples R China
关键词
Primary central nervous system lymphoma; Pemetrexed; Rituximab; Second-line treatment; B-CELL LYMPHOMA; HIGH-DOSE METHOTREXATE; SALVAGE TREATMENT; TEMOZOLOMIDE; GLIOBLASTOMA; MICRORNAS; RECURRENT; THERAPY; MARKER; SERUM;
D O I
10.1007/s12032-014-0351-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to determine the efficacy and toxicity of pemetrexed plus rituximab in patients with primary central nervous system lymphoma, who had undergone treatment with high-dose (HD) methotrexate-based regimens. Patients who had failed HD methotrexate-based regimens treatment had ECOG performance status ranging from 0 to 2. Twenty-seven patients received pemetrexed plus rituximab as second-line treatment. Rituximab 375 mg/m(2) was administered on day 0 and pemetrexed 500 mg/m(2) was administered on day 1 every 3 weeks. Six patients (22.2 %) experienced CR, 11 patients (40.7 %) had PR, eight patients (29.6 %) had SD, and two patients had PD. The response rate was 62.9 %. The median time to progression (PFS) was 6.9 months (95 % CI, 5.6-8.3), and the median overall survival was 11.2 months (95 % CI, 9.1-13.4). In the subgroup analysis, PFS had a significant difference among the low-level of serummiR-21 and high level of serummiR-21. PFS was 9.0 (95 % CI, 6.3-11.6) and 5.7 months (95 % CI, 4.6-6.9, log rank = 0.015), respectively. None of the patient experienced grade 4 toxicity. A regimen of pemetrexed combined with rituximab is marginally effective and well tolerated in patients with PCNSL who had failed HD methotrexate-based regimens first-line treatment.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 24 条
[1]   Primary central nervous system lymphoma [J].
Abrey, Lauren E. .
CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) :675-680
[2]   Rituximab significantly improves complete response rate in patients with primary CNS lymphoma [J].
Birnbaum, Tobias ;
Stadler, Elisabeth Anne ;
von Baumgarten, Louisa ;
Straube, Andreas .
JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (02) :285-291
[3]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[4]   Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002 [J].
Ferreri, AJM ;
Abrey, LE ;
Blay, JY ;
Borisch, B ;
Hochman, J ;
Neuwelt, EA ;
Yahalom, J ;
Zucca, E ;
Cavalli, F ;
Armitage, J ;
Batchelor, T .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2407-2414
[5]   High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial [J].
Ferreri, Andres J. M. ;
Reni, Michele ;
Foppoli, Marco ;
Martelli, Maurizio ;
Pangalis, Gerasimus A. ;
Frezzato, Maurizio ;
Cabras, Maria Giuseppina ;
Fabbri, Alberto ;
Corazzelli, Gaetano ;
Ilariucci, Fiorella ;
Rossi, Giuseppe ;
Soffietti, Riccardo ;
Stelitano, Caterina ;
Vallisa, Daniele ;
Zaja, Francesco ;
Zoppegno, Lucia ;
Aondio, Gian Marco ;
Avvisati, Giuseppe ;
Balzarotti, Monica ;
Brandes, Alba A. ;
Fajardo, Jose ;
Gomez, Henry ;
Guarini, Attilio ;
Pinotti, Graziella ;
Rigacci, Luigi ;
Uhlmann, Catrina ;
Picozzi, Piero ;
Vezzulli, Paolo ;
Ponzoni, Maurilio ;
Zucca, Emanuele ;
Caligaris-Cappio, Federico ;
Cavalli, Franco .
LANCET, 2009, 374 (9700) :1512-1520
[6]   Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors [J].
Jahnke, Kristoph ;
Thiel, Eckhard ;
Martus, Peter ;
Herrlinger, Ulrich ;
Weller, Michael ;
Fischer, Lars ;
Korfel, Agnieszka .
JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (02) :159-165
[7]   Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma [J].
Lawrie, Charles H. ;
Gal, Shira ;
Dunlop, Heather M. ;
Pushkaran, Beena ;
Liggins, Amanda P. ;
Pulford, Karen ;
Banham, Alison H. ;
Pezzella, Francesco ;
Boultwood, Jacqueline ;
Wainscoat, James S. ;
Hatton, Christian S. R. ;
Harris, Adrian L. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (05) :672-675
[8]   Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma [J].
Ma, Xinlong ;
Yoshimoto, Koji ;
Guan, Yaulei ;
Hata, Nobuhiro ;
Mizoguchi, Masahiro ;
Sagata, Noriaki ;
Murata, Hideki ;
Kuga, Daisuke ;
Amano, Toshiyuki ;
Nakamizo, Akira ;
Sasaki, Tomio .
NEURO-ONCOLOGY, 2012, 14 (09) :1153-1162
[9]   Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma [J].
Mao, Xuhua ;
Sun, Yuan ;
Tang, Junming .
NEUROLOGICAL SCIENCES, 2014, 35 (02) :233-238
[10]   Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy [J].
Mappa, Silvia ;
Marturano, Emerenziana ;
Licata, Giada ;
Frezzato, Maurizio ;
Frungillo, Niccolo ;
Ilariucci, Fiorella ;
Stelitano, Caterina ;
Ferrari, Antonella ;
Soraru, Mariella ;
Vianello, Fabrizio ;
Baldini, Luca ;
Proserpio, Ilaria ;
Foppoli, Marco ;
Assanelli, Andrea ;
Reni, Michele ;
Caligaris-Cappio, Federico ;
Ferreri, Andres J. M. .
HEMATOLOGICAL ONCOLOGY, 2013, 31 (03) :143-150